Eye disorders in diabetes: Potential drug targets

Infectious Disorders - Drug Targets

Volumn 8, Issue 2, 2008, Pages 70-75

  Josifova, T ^a   Schneider, U ^a   Henrich, P B ^a   Schrader, W ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Diabetic retinopathy; Hypoxia; Intravitreal drugs; Maculopathy; Neovascularisation; VEGF

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSE REDUCTASE INHIBITOR; ALPHA INTERFERON; ANTIHYPERTENSIVE AGENT; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CORTICOSTEROID; DOBESILATE CALCIUM; GLUCOSE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; PEGAPTANIB; PENTOXIFYLLINE; PLACEBO; RANIBIZUMAB; RUBOXISTAURIN; SOMATOMEDIN C; TICLOPIDINE; TRIAMCINOLONE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD RETINA BARRIER; CATARACT; CLINICAL TRIAL; CONJUNCTIVITIS; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIABETIC MACULAR EDEMA; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG TARGETING; ENDOPHTHALMITIS; EYE DISEASE; HERPES; HUMAN; HYPERGLYCEMIA; INFECTION RISK; INTRAOCULAR HYPERTENSION; KERATITIS; LASER COAGULATION; LOW LEVEL LASER THERAPY; MORBIDITY; OPTIC NERVE DISEASE; PATHOGENESIS; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA DETACHMENT; RETINA MACULOPATHY; RISK FACTOR; THERAPY EFFECT; VITRECTOMY; VITREOUS HEMORRHAGE;

CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEMS; EYE DISEASES; HUMANS; RISK FACTORS;

EID: 46649100492     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152608784746529     Document Type: Article

References (50)

1. Blum, M.; Kloos, C.; Muller, N. Ophthalmologe, 2007, 104, 6.
2. Gandorfer, A.; Messmr, E.M.; Ulbig, M.W.; Kampik, A. Retina, 2000, 20, 126.
3. Kurse, A.; Thomsen, R.W.; Hundborg, H.H.; Kundsen, L.L.; Sorensen, H.T.; Schonheyder, H.C. Diabet. Med., 2006, 23, 393.
4. Melo, G.B.; Hofling-Lima, A.L.; Alvarenga, L.S.; Monteiro, A.C. Br. J. Ophthalmol., 2006, 90, 916.
5. Guyer, D.R.; Yannuzi, L.A.; Chang, S.; Green, R.W. W.B. Saunders Company 1999.
6. Trautner, C. www.medizin-aktuell.de/, 2008.
7. American Academy of Ophthalmology. 2002. http://www.aao.org
8. Lewis, H.; Ryan, R.S. Medical and Surgical Retina. Mosby 1994, 257.
9. Kent, D.; Vinores, S.A.; Campochiaro, P.A. Br. J. Ophthalmol., 2000, 84, 542.
10. Keech, A.C.; Mitchell, P.; Summannen, P.A. Lancet, 2007, 370, 1687.
11. Orgül S: (Eds) Pharmacotherapy in Glaucoma, Verlag Hans Huber 2000.
12. Aiello, L.M. Am. J. Ophthalmol., 2003, 136, 122.
13. Priglinger, S.G.; Krentzer, T.C. www.Pharmazeutische-zeitung.de 2008
14. Stur, M.; Egger, S.; Huas, A.; Kiselbach, G. et al: Acta Medica Austrica, 2004, 5, 179.
15. Beckendorf, A.; Kusserow, C.; Schmidt-Erfurth, U. Ophthalmologica, 2007, 221, 118.
16. Clermont, A.C.; Tagaki, C.; Jirousek, M.R. Invest. Ophthalmol. Vis. Sci., 1995, 35, S 172.
17. Tesfamariam, B.; Brown, M.L.; Cohen, R.A. J. Clin. Invest., 1991, 87, 1643.
18. Greene, D.A.; Lattimer, S.A.; Sima, A.A.F. N. Engl. J. Med., 1987, 316, 359.
19. Meyer, P.; Lang, M.G.; Flammer, J.; Lüscher, T. Exp. Eye Res., 1995, 60, 505.
20. The Diabetic Retinopathy study Research Group. Arch. Ophthalmol., 1979, 97, 654.
21. The Diabetic Retinopathy study Research Group. Invest. Ophthalmol. Clin., 1994, 27, 239.
22. Carsten, H.M. Ophthalmologica, 2007, 221, 118.
23. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology, 1987, 94, 761.
24. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology, 1991, 98, 766.
25. Early Treatment Diabetic Retinopathy Study Research Group. Am. J. Ophthalmol., 1999, 127, 137.
26. Sebag, J.; Buckingham, B.; Charles, M.A.; Reiser, K. Arch. Ophthalmol., 1992, 110, 1472.
27. Teiko, Y.; Naoko, A.; Shinobu, T. Am. J. Ophthalmol., 2001, 132, 369.
28. Sebag, J.; Nie, S.; Reiser, K. Invest. Ophthalmol. Vis. Sci., 1994, 35, 2976.
29. Sebag, J.; Balazes, E.A. Surv. Ophthalmol., 1984, 29, 493.
30. Ferrari, T.M.; Cardascia, N.; Durante, G.; Vetrugno, M.; Cardia, L. Doc. Ophthalmol., 1999, 97, 471.
31. Kumagai, K.; Ogino, N.; Furukawa, M.; Demizu, S.; Atsumi, K.; Kurihara, H.; Iwaki, M.; Ishigooka, H.; Tachi, N. Nippon Ganka Gakkai Zasshi, 2002, 106, 590.
32. Kuhn, F.; Kiss, G.; Mester, V.; Szijarato, Z.; Kovacs, B. Graefes Arch. Clin. Exp. Ophthalmol., 2004, 242, 402.
33. La Heij, E.C.; Hendrikse, F.; Kessels, A.G.; Derhaag, P.J. Graefes Arch. Clin. Exp. Ophthalmol., 2001, 239, 264.
34. Lewis, H.; Abrams, G.W.; Blumenkranz, M.S.; Campo, R.V. Ophthalmology, 1992, 99, 753.
35. Lewis, H. Am. J. Ophthalmol., 2001, 131, 123.
36. Haefliger, I.; Meyer, P.; Flammer, J.; Lüscher, T. Surv. Ophthalmol., 1994, 39, 123.
37. Adamis, A.P.; Miller, J.W.; Bernal, M.T. Am. J. Ophthalmol., 1994, 118, 445.
38. Adamis, A.P.; Shima, D.T.; Yeo, K.T. Biochem. Biophys. Res. Commun., 1993, 193, 631.
39. Watanabe, D.; Suzuma, K.; Suzuma, I.; Ohashi, H.; Ojima., T.; Kurimoto, M.; Murakami, T.; Kimura, T.; Takagi, H. Am. J. Ophthalmol., 2005, 139, 476.
40. Hirrotaka, I.; Shoji, K.; Nobuo, K.; Masami, M. Ophthalmology, 2004, 111, 1880.
41. Martidis, A.; Duker, J.S.; Greenberg, P.B.; Rogers, A.H.; Puliafito, C.A.; Reichel, E.; Baumal, C. Ophthalmology, 2002, 109, 920.
42. Wilson, C.A.; Berkowitz, B.A.; Sato, Y. Arc. Ophthalmol., 1992, 110, 1155.
43. Cellini, M.; Pazzaglia, A.; Leonetti, P.; Campio, E. BMC Ophthalmol., 2008, 8, 5.
44. Jonas, J.B.; Kreissig, I.; Solker, A.; Degenring, R.F. Arch. Ophthalmol., 2003, 121, 57.
45. Jonas, J.B.; Kreissig, I.; Degenring, R. Arch. Ophthalmol., 2003, 121, 729.
46. Jonas, J.B. Ophthalmologe, 2004, 101, 111.
47. Charters, L. http://ophthalmologytimes.modemmedicine.com/, 2008
48. Mosfhegi, D.M.; Kaiser, P.K.; Scott, I.U. Am. J. Ophthalmol., 2003, 136, 791.
49. Jaisle, G.B.; Szurman, P.; Bartz-Schimdt, K.U. Klin. Monatsbl. Augenheilkd., 2005, 222, 390.
50. Michels, S.; Agostini, H. Inhibition der angiogenese in der Augenheilkunde, UNI-MED Verlag, 2007.